Trial Profile
The effect of CES1A genetic polymorphism on the pharmacokinetics of Oseltamivir.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Feb 2013
Price :
$35
*
At a glance
- Drugs Oseltamivir (Primary)
- Indications Influenza virus infections
- Focus Pharmacogenomic; Pharmacokinetics
- 21 Jun 2011 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 24 Jan 2011 New trial record